FDA OKs Tesaro’s Zejula in recurrent ovarian cancer
Nanoparticle could lead to new treatments for triple negative breast cancer
FDA approves first ever drug for rare skin cancer
Lilly’s abemaciclib provides positive data, plans for NDA later this year
Further good news for AZ’s Lynparza as it impresses in key phase 3 ovarian cancer study
Advanced proton therapy shows promise in recurrent lung cancer
NICE says no to J&J’s Darzalex in multiple myeloma
Google-created AI capable of detecting breast cancer better than pathologists
Cancer Matters 